Stockscreener 앱 받기
4.68
1.30%
0.06
시간 외 거래:
4.67
-0.010
-0.21%
전일 마감가:
$4.62
열려 있는:
$4.53
하루 거래량:
7,479
Relative Volume:
0.04
시가총액:
$2.65M
수익:
$927.00K
순이익/손실:
$-13.21M
주가수익비율:
-0.0222
EPS:
-210.8843
순현금흐름:
$-4.77M
1주 성능:
+21.56%
1개월 성능:
-7.72%
6개월 성능:
-88.82%
1년 성능:
+40.54%
1일 변동 폭
$4.38
$4.68
1주일 범위
$3.80
$4.82
52주 변동 폭
$2.034
$80.10
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
4.68 | 2.44M | 927.00K | -13.21M | -4.77M | -210.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.59 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.12 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.77 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.80 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.29 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scisparc Ltd 주식(SPRC)의 최신 뉴스
SciSparc (SPRC) director discloses shares, options and RSU awards - Stock Titan
SciSparc (SPRC) director reports initial share and option holdings - Stock Titan
SciSparc (SPRC) director Revach Moshe discloses initial share and RSU holdings - Stock Titan
SciSparc (SPRC) CEO Adler Oz details share, option and RSU holdings - Stock Titan
SciSparc (SPRC) director Weiss Amitay details equity holdings - Stock Titan
SciSparc (SPRC) director Vider Lior details shares, options and RSUs - Stock Titan
SciSparc (SPRC) CTO details 5,528 Ordinary Shares and option holdings on Form 3 - Stock Titan
SciSparc (SPRC) director reports 3,651-share stake and RSU grants - Stock Titan
Sentiment Watch: Can SciSparc Ltd stock outperform in a bear marketRecession Risk & Expert Verified Stock Movement Alerts - baoquankhu1.vn
SciSparc stock rallies after AutoMax files motion on pending merger - MSN
Buyout Rumor: Is SciSparc Ltd impacted by rising ratesMarket Performance Report & Low Drawdown Investment Ideas - baoquankhu1.vn
SciSparc subsidiary files patent for depression treatment By Investing.com - Investing.com India
[SCHEDULE 13G] SciSparc Ltd. Passive Investment Disclosure (>5%) - Stock Titan
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing - TipRanks
SciSparc (NASDAQ: SPRC) collaboration advances MEAI-PEA depression patent bid - Stock Titan
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Bitget
SciSparc subsidiary files patent for depression treatment - Investing.com
SciSparc Ltd. Reports NeuroThera Labs' Patent Application for Innovative Depression Treatment Combining MEAI and PEA - Quiver Quantitative
Non-hallucinogenic depression combo MEAI-PEA seeks Hong Kong patent - Stock Titan
SciSparc Subsidiary NeuroThera to Take Majority Stake in Quantum Trials Firm CliniQuantum - TipRanks
SciSparc (Nasdaq: SPRC) unit to acquire 54% of CliniQuantum and lose NeuroThera control - Stock Titan
SciSparc’s Neurothera Labs announces publication of international patent - TipRanks
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
SciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD. - Quiver Quantitative
SciSparc: $9.46 Million NeuroThera Deal To Acquire Majority Stake In Quantum Clinical Trials Firm CliniQuantum - Pulse 2.0
SciSparc, Subsidiary NeuroThera Labs Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails - marketscreener.com
SPRC Stock Price, Quote & Chart | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
NeuroThera to acquire 54% stake in quantum tech firm CliniQ - Investing.com South Africa
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails - Bitget
SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum - TipRanks
SciSparc Ltd. Subsidiary NeuroThera Labs Inc. Enters Share Purchase Agreement to Acquire Majority Stake in CliniQuantum Ltd. - Quiver Quantitative
Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd. - TheNewswire
Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd. (2026-03-10) - Seeking Alpha
Quantum trials deal: NeuroThera swaps $9.46M stock for majority CliniQ stake - Stock Titan
SciSparc Ltd. (SPRC) Schedule 13G/A amendment shows holder ≤5% - Stock Titan
Can SciSparc Ltd. stock resist market sell offsJuly 2025 Update & Accurate Trade Setup Notifications - Naître et grandir
Aug Reactions: What is the implied volatility of SciSparc LtdEarnings Summary Report & Fast Gain Stock Trading Tips - baoquankhu1.vn
Analyst Upgrade: Whats the beta of SciSparc Ltd stockPortfolio Update Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SciSparc announces publication of Japanese patent application - MSN
SciSparc announces 1-for-9 reverse share split - Yahoo Finance
SciSparc to implement 1-for-9 reverse stock split Wednesday - Investing.com India
SciSparc to Enact 1-for-9 Reverse Share Split as Outstanding Shares Shrink - The Globe and Mail
SPRC SEC FilingsScisparc 10-K, 10-Q, 8-K Forms - Stock Titan
SciSparc to implement 1-for-9 reverse stock split Wednesday By Investing.com - Investing.com Canada
SciSparc Falls 12% After Announcing 1-for-9 Reverse Share Split - Nasdaq
SciSparc Announces 1-for-9 Reverse Share Split - The Manila Times
SciSparc (NASDAQ: SPRC) to implement 1-for-9 reverse share split - Stock Titan
SciSparc Amends $10 Million Note Deal, Issues $2 Million Initial Convertible Note - TipRanks
SciSparc (SPRC) arranges up to $10M discounted convertible note deal - Stock Titan
Is SciSparc Ltd. stock safe for conservative investorsShare Buyback & Target Return Focused Stock Picks - mfd.ru
Scisparc Ltd (SPRC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
자본화:
|
볼륨(24시간):